Research programme: anti-HIV antibody - Biolex

Drug Profile

Research programme: anti-HIV antibody - Biolex

Alternative Names: Anti-HIV antibody research programme - Biolex; sCD4-17b

Latest Information Update: 16 Jul 2007

Price : $50

At a glance

  • Originator Biolex
  • Developer Biolex; Dow Chemical
  • Class Antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued HIV infections

Most Recent Events

  • 16 Jul 2007 Discontinued - Preclinical for HIV infections prevention in USA (Topical)
  • 06 May 2004 Epicyte Pharmaceutical has been acquired and merged into Biolex
  • 25 Oct 2002 Epicyte has been awarded a NIH grant for the large-scale production of hybrid antibodies to block the tranasmission of HIV
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top